|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2002-3-6
|
|
pubmed:abstractText |
Subthalamic nucleus (STN) deep brain stimulation (DBS) of patients with PD allows reduction of antiparkinsonian medication but has only a mild direct effect on dyskinesia. Since antiparkinsonian medication has short- and long-term effects that may prevent an estimate of the maximal possible impact of STN DBS, such medication was used at the lowest possible dosage after DBS implantation.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0028-3878
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
12
|
|
pubmed:volume |
58
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
396-401
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:11839838-Aged,
pubmed-meshheading:11839838-Antiparkinson Agents,
pubmed-meshheading:11839838-Combined Modality Therapy,
pubmed-meshheading:11839838-Electric Stimulation Therapy,
pubmed-meshheading:11839838-Female,
pubmed-meshheading:11839838-Follow-Up Studies,
pubmed-meshheading:11839838-Humans,
pubmed-meshheading:11839838-Levodopa,
pubmed-meshheading:11839838-Male,
pubmed-meshheading:11839838-Middle Aged,
pubmed-meshheading:11839838-Parkinson Disease,
pubmed-meshheading:11839838-Subthalamic Nucleus,
pubmed-meshheading:11839838-Treatment Outcome
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Subthalamic DBS replaces levodopa in Parkinson's disease: two-year follow-up.
|
|
pubmed:affiliation |
Department of Neurology, BH 13, CHUV, CH-1011 Lausanne, Switzerland. francois.vingerhoets@chuv.hospvd.ch
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|
